DCF Advisers LLC Has $2.06 Million Position in LENSAR, Inc. (NASDAQ:LNSR)

DCF Advisers LLC lessened its holdings in shares of LENSAR, Inc. (NASDAQ:LNSR) by 4.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 230,055 shares of the company’s stock after selling 10,545 shares during the period. DCF Advisers LLC owned 1.98% of LENSAR worth $2,057,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Brandes Investment Partners LP grew its holdings in LENSAR by 10.4% during the 4th quarter. Brandes Investment Partners LP now owns 489,318 shares of the company’s stock worth $4,375,000 after acquiring an additional 45,920 shares during the period. Geode Capital Management LLC grew its holdings in LENSAR by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after acquiring an additional 3,423 shares during the period. Essex Investment Management Co. LLC grew its holdings in LENSAR by 18.3% during the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock worth $357,000 after acquiring an additional 6,184 shares during the period. Atria Investments Inc grew its holdings in LENSAR by 28.2% during the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock worth $233,000 after acquiring an additional 5,729 shares during the period. Finally, Bailard Inc. acquired a new stake in LENSAR during the 4th quarter worth $181,000. Institutional investors and hedge funds own 40.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital lifted their target price on shares of LENSAR from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, February 28th.

LENSAR Stock Down 8.7 %

Shares of NASDAQ LNSR opened at $15.40 on Friday. The company’s fifty day moving average is $11.31 and its 200-day moving average is $8.06. The stock has a market cap of $181.55 million, a price-to-earnings ratio of -10.55 and a beta of 0.62. LENSAR, Inc. has a twelve month low of $2.67 and a twelve month high of $17.31.

LENSAR (NASDAQ:LNSR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). The firm had revenue of $16.73 million for the quarter, compared to the consensus estimate of $14.95 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.

LENSAR Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.